Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014

Table 1 Overall M. genitalium prevalence and number of M. genitalium positive specimens after confirmation testing (2007–2014)

Year	Study^*	Males					Females
		N	M. genitalium prevalence		M. genitalium used in this study after confirmation		N	M. genitalium prevalence		M. genitalium used in this study after confirmation
		N	n	%^#	n	%^§	N	n	%^#	n	%^§
2007	NMS	205	31	15.1	2	6.5	200	23	11.5	1	4.3
2007	PLWHA	550	39	7.1	16	41.0	558	29	5.2	8	27.6
2008	NMS	433	37	8.5	14	37.8	312	32	10.3	13	40.6
2009	NMS	499	45	9.0	13	28.9	492	40	8.1	7	17.5
2010	NMS	427	38	8.9	27	71.1	393	51	13.0	36	70.6
2011	NMS	261	21	8.0	16	76.2	220	19	6.4	15	78.9
2012	NMS	198	16	8.1	15	93.8	207	20	9.7	16	80.0
2013	NMS	280	23	8.2	13	56.5	199	27	13.6	25	92.6
2014	NMS	206	11	5.3	10	90.9	199	24	12.1	19	79.2
Total	Total	3059	261	8.5	126	48.3	2780	265	9.5	140	52.8

^* NMS National Microbiological Surveillance study (symptomatic patients), PLWHA People living with HIV/AIDS study (asymptomatic patients)
^# Percentage of genital discharge specimens that initially tested positive for M. genitalium
^§ Percentage of stored DNA specimens that tested M. genitalium positive after confirmatory testing in this study